Biotech and Pharmaceuticals Pharmaceuticals

More

  • lipitor_bottle_200.jpg

    Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman.

  • Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.

  • obesity_man_200.jpg

    I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.

  • Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell. The Dow jumped more than 2 percent—its best day since July.

  • On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck and the company it's buying, Schering-Plough, are sliding. So, what gives?

  • Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell.

  • Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell.

  • Futures pointed to a positive open for Wall Street on Thursday ahead of the all-important U.S. third-quarter gross domestic product data.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks tumbled to session lows late Wednesday, with the Dow down more than 100 points, as worries about the recovery gripped the market.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks were lower at the halfway point Wednesday as investors shrugged off some good news and worries about the recovery gripped the market.

  • Stocksskidded Wednesday, despite a rise in durable-goods orders and some earnings beats, as worries about the recovery dragged on the market.

  • gsk_logo.jpg

    GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.

  • The weak consumer confidence report that hit U.S. stocks on Tuesday is having a lingering effect this Wednesday, with global stock markets falling and stock index futures pointing to another lower open on Wall Street.

  • Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • Amgen

    Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.

  • Eli_Lilly_200.jpg

    The folks at Eli Lilly probably cringe every time I go here, but the company this morning reported that third quarter U.S. sales of the erectile dysfunction drug Cialis sprung 13 percent to nearly $159 million.

  • earnings_central_badge.jpg

    One of the things we learned in Pfizer's earnings press release and on the conference call today is that since the start of 2008 the company has eliminated 11,200 positions. And now that the world's biggest pharmaceutical firm has gotten even bigger by swallowing Wyeth, it's going to let go even more people to help wring out about $4 billion in annual expenses by 2012.

  • Pfizer's acquisition of Wyeth will add to the pharmaceutical giant's diversity, which over time will help boost the company's stock, CEO Jeff Kindler told CNBC Tuesday.

  • Amgen

    In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.

  • Stocks pared some of their earlier losses but were still lower as disappointing results from Bank of America and General Electric eclipsed strong results from big techs.